Cohort (n=110)
The study aims to develop a new echocardiographic prognostic score (PROBE) for patients with end-stage heart failure to predict major adverse cardiac events.
Answers are grounded in this paper and cite their sources.
May refine end-stage HF risk stratification; leaves open prospective validation before changing allocation.
Introduction: End Stage Heart Failure (ESHF) is refractory to medical therapy and characterized by high incidence of Major Adverse Cardiac Events (MACEs). To optimize the limited available therapeutic resources, mainly heart transplantation (HTX) and Left Ventricular Assist Device (LVAD) implantation, the identification of the best outcome predictors is paramount. Purpose: The aim of our study was to create a new prognostic score, based on echocardiography, which could integrate and overcome the limitations of the currently used scores. Methods: We enrolled 110 patients with ESHF referred to our echo lab in 2013–2016. All subjects underwent standard, 3D and Speckle Tracking Echocardiography. The exclusion criteria included: previous valvular surgery, elective HTX or LVAD implantation, atrial fibrillation, poor acoustic window and lack of informed consent. Patients were prospectively followed for a mean period of 2±0.7 years and the following MACEs were recorded: cardiovascular death, hospitalizations for acute HF, emergency HTX, LVAD implantation or IABP implantation.
No takes yet. Share an insight, caveat, or question.
Mandoli et al. (2018) conducted a cohort in End-stage heart failure (n=110). Echocardiographic prognostic stratification (PROBE score) was evaluated on Major Adverse Cardiac Events (cardiovascular death, hospitalizations for acute HF, emergency HTX, LVAD implantation or IABP implantation).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: